Electrical muscle stimulation technology refers to the in-duction of skeletal muscle contractions through the appli-cation of electrical currents, thereby generating movement or enhancing muscle ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Years ago, no math education was complete without understanding how to compute a square root. Today, you are probably just reaching for a calculator, or if you are writing a program, you’ll probably ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

In an era dominated by social media, misinformation has become an all too familiar foe, infiltrating our feeds and sowing seeds of doubt and confusion. With more than half of social media users across ...

ABSTRACT: A hyperbolic model for the diffusion of proteins through the blood-cerebrospinal fluid (CSF) barrier revolutionized clinical neurochemistry thirty years ago. The regression curves were ...

Investors sold out of the biotech following a quarterly earnings release this morning. The company posted a deeper-than-expected net loss. It's common for clinical-stage biotech companies to post net ...

The company laid out its restructuring plans in a regulatory document. These include a workforce reduction of around 20%. Before market open, Recursion disclosed in a tersely worded regulatory filing ...